Trial Profile
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2879552 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 13 Aug 2018 Status changed from active, no longer recruiting to discontinued as the risk benefit in relapsed refractory AML does not favor continuation of the study
- 03 Apr 2018 Status changed to active, no longer recruiting.
- 30 Jan 2018 Status changed from recruiting to discontinued as the risk benefit in relapsed refractory AML does not favor continuation of the study